Zebra Medical Vision Unveils AI-Based Chest X-ray Research | Tech News
June 8, 2018 — Zebra Medical Vision unveiled its Textray chest X-ray research, which will form the basis for a future artificial intelligence (AI)-based automated chest X-ray analysis product the company is developing. Simultaneously, the company announced it has raised $30M in C round funding, bringing the total investment in the company to $50M.
This round of investment is led by aMoon Ventures, with the participation of strategic healthcare investors Aurum, Johnson & Johnson Innovation JJDC Inc. and Intermountain Healthcare, and leading global AI scientists Prof. Fei Fei Lee and Richard Socher. These new investors are joining a list of existing investors that includes Khosla Ventures, NVIDIA, Marc Benioff, OurCrowd and Dolby Ventures, who also participated in this C round.
The chest X-ray AI analytics product was trained using nearly 2 million images to identify 40 different common clinical findings. The results of the study demonstrate high rates of agreement between the algorithm and human radiologist experts.
Zebra Medical Vision has received the CE regulatory mark for seven of its products, as well as approvals in numerous countries across Latin America and Asia. Its most recent announcements were the CE approval of computed tomography (CT) brain bleed and mammography lesion detection algorithms. The company’s current and future arsenal of AI algorithms is bundled into a unique $1 per scan offering to hospitals, in order to provide scalable, transparent and affordable care solutions.
“Medical experts worldwide are facing a critical challenge in handling overwhelming demand. We are excited to partner with the Zebra-Med team, which is harnessing the power of data and machine learning to provide physicians and healthcare systems with tools to dramatically increase capacity, while improving patient care,” said Yair Schindel, M.D., managing partner at aMoon VC. “This investment aligns with our vision of backing scalable and sustainable innovations that will have a valuable impact on fundamental facets of global healthcare.”
For more information: www.zebra-med.com